Jonathan's practice involves providing commercially-focussed advice on patent origination, patent strategy and portfolio management, licensing and due diligence, prosecuting and defending European patent oppositions, and conducting patent litigation in the UK and Europe.
His practice draws in this variety of experience and extends to a wide range of chemical and pharmaceutical subject matter. Jonathan's practice in the pharmaceutical area has covered both contentious and non-contentious issues and he has provided external consultancy services to a number of large pharmaceutical companies over the last 20 years.
His practice involves providing commercially focused advice to C-suite business leaders, R&D groups, and public institutions on all aspects of patent strategy and portfolio management. This includes obtaining and defending patent rights, providing opinions on freedom to operate where third party intellectual property rights exist, conducting due diligence to support corporate acquisition and licensing deals, challenging third party patent rights and pan-European pharmaceutical litigation.
Jonathan has worked on a number of high profile pharmaceutical matters including working as part of the patent procurement team for Viagra™; prosecution and litigation surrounding Augmentin™, Ritalin™ and Fosrenol™; opposition/appeal work on Zithromax™, Perindopril and Sovaldi™ and due diligence work to support acquisitions (eg New River Pharmaceuticals and Renovo, and IPO's (eg Redx and NuCana plc), and private equity investment funding (eg OriBiotech).
In the non-pharmaceutical area, he has been responsible for filing all of the foundation patents for graphene on behalf of Manchester University's two Nobel Prize winners Geim and Novoselov.
Jonathan's clients include large and small companies, universities and government organisations.
Cert in IP Law Queen Mary, London
C. Chem, FRSC
Oral proceedings by videoconference can be enforced by the EPO during the pandemic On 16 July 2021 the EPO’s Enlarged Board of Appeal (EBoA) decided on referral G 1/21 regarding …Read article
HGF in Europe and Shiga in Japan are holding a joint webinar on 29th July 2021. Fitter, faster, stronger – patenting sports and fitness technology in Europe and Japan Sporting …Event details
The IAM Patent 1000 – the world’s leading patent professionals 2021 guide has now been published. HGF has 18 European attorneys listed. IAM Patent 1000 is a unique guide that …Read article
WIPR Patents Live is holding a complimentary session on July 20, at 5pm BST/12pm ET, where HGF Partner & Patent Attorney Kieran Killough will present on ‘Protecting medical devices in …Event details
G1/21 hearing continues on 2nd July 2021. Follow this page for updates from HGF Partner Douglas Drysdale and Patent Director Ellie Purnell, who will be reporting all the key moments …Read article
HGF is hosting a ‘Patents for the offshore sector’ webinar on 13th July, 2021. The webinar will be presented by HGF Patent Director Richard Gover. It will include an introduction …Event details
The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’. Such a refusal can …Read article
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.